汇集所有期刊的论文。启动研究智能体，持续关注你的主题。
While very interesting that 91% had positive CVB serologies, prevalence is probably not the best term to use, as to be included in the analysis, patients had to have sarcoidosis and available CVB testing. Prevalence could be defined if all sarcoidosis patients had CVB testing.
Open HeartDonnelly et al.
ESC Congress 2026 · SWITCH SWEDEHEART
Great study pioneering to use of cluster randomization in registries to test different treatment strategies in real life. Very useful cost-effective model when implementing novel treatment strategies in the real life setting. The comparison of the strategies "prasugrel first choice" vs "ticagrelor first choice" turned out neutral on efficacy - safety difficult to evaluate in this setting. Good to have two similar alternatives to tailor to different patients and settings.
New England Journal of MedicineElmir Ömerovic et al.
Interventional Cardiologist · Charles University and University Hospital Kralovske Vinohrady
“借鉴已用于心脏病发作的成熟方案，我们得以证实，在我们国家网络的各级三级医疗中心均可开展专业介入治疗。这可能为改善和标准化肺栓塞治疗方法铺平道路，从而降低患者面临的急性风险。”
New England Journal of MedicineKroupa et al.
ESC Congress 2026 · HIS Alternative II
this is an interesting first take. A well done study but limited by duration of follow up and sample size. It does seem to indicate when the procedure is well done, actually both procedures well done there may not be that much difference between both techniques.
JACC. Clinical electrophysiologyMichael Vinther et al.
“在这些高危患者中，在药物治疗的基础上进行经导管三尖瓣修复不仅改善了生活质量，而且有意义且持续地降低了硬性临床结局事件，这在该介入治疗中是前所未有的。”
New England Journal of MedicineHausleiter et al.
Lead Researcher · Monash University School of Public Health and Preventive Medicine
“一个值得注意的发现是，与安慰剂相比，atorvastatin 治疗下主要非致死性心血管事件发生率的降低并没有带来无残疾生存期的相应改善。对该结果的可能解释包括试验中 80% 的死亡是由非心血管原因引起的。”
New England Journal of MedicineZoungas et al.
“对临床实践的关键影响在于，关于该人群的证据水平实际上非常低，而这是第一项支持 DOAC 治疗可为该患者人群带来获益的[随机对照试验]。”
New England Journal of MedicineKim et al.
Cardiologist · Copenhagen University Hospital
“从 POET I 和 POET II 来看，我们似乎打破了既往观念，表明病情稳定后进行强度较低的抗生素治疗更具优势且安全。我们认为，明确病情稳定这一时间点，本身就是心内膜炎个体化治疗的一种体现。”
New England Journal of MedicineBundgaard et al.
ESC Congress 2026 · AMUNDSEN
Why didn’t achieving an LDL-C of 16mg/dl 6 weeks after MI and an LDL-C difference between groups of 40mg/dl at week 6 with the aforementioned rationale translate into significant clinical benefits at 1 year?
JAMAGilles Montalescot et al.
Professor of Emergency Medicine · The Usher Institute, University of Edinburgh
尽管即时 ECG 监测并未减少晕厥复发，但它能够更早发现严重的心律失常，使患者能够更早接受治疗，减少不确定性和焦虑，并可能预防可避免的死亡。
New England Journal of MedicineReed et al.
Expert commentary · @gbiondizoccai
在纳入 986 例患者的 TAVI PCI RCT 中，对于同时患有主动脉瓣狭窄和 CAD（25% MVD）的患者，PCI 前行 TAVI 策略与 TAVI 前行 PCI 策略在 1 年时的结局相似 https://t.co/8d0elI9CeM #CAD #PCI #TAVI #TAVR @NEJM @escardio https://t.co/OEZFeSNXLq
New England Journal of MedicineStähli et al.
Cardiologist · Oregon Health & Science University
ACACIA-HCM 试验的结果为有症状的非梗阻性 HCM 患者带来了非常积极的消息。我们首次通过针对病因的治疗，展示了患者在症状和运动能力方面具有临床意义的改善。
New England Journal of MedicineMasri et al.
ESC Congress 2026 · STAREE
Cardiology
Key Question
Should statin initiation in older adults be individualized rather than age-based?
Individualized, considering function (and CAC), not age to identify risk and time to benefit. CAC of zero in up to 18% of primary prevention age 75+ population.
New England Journal of MedicineSophia Zoungas et al.
Cardiologist · Nanjing First Hospital
尽管药物和器械治疗取得了重大进展，但在左心疾病和心力衰竭患者中，肺动脉高压仍然是预测住院、右心室衰竭和死亡的最强预测因素之一。……进一步的长期随访对于确定所观察到的中期改善是否能转化为死亡率和 HF 住院率的持续降低至关重要。
New England Journal of MedicineZhang et al.
BHF Professor of Cardiology, University of Edinburgh · University of Edinburgh
“我们的研究结果提供了有力证据，表明已排除心脏病发作的患者并不能从早期门诊 CTCA 扫描中获益。一旦我们确信他们没有发生心脏病发作，就可以向这些患者保证他们未来的风险较低，并让他们回家。”
New England Journal of MedicineLee et al.